Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer: Advanced Disease

June 12, 2014

Join Ingrid Mayer, MD, and Ingrid Meszoely, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Breast Cancer - Advanced Disease.

Breast cancer is the most commonly diagnosed cancer in American women. The American Cancer Society estimates that 235,030 women will be diagnosed with breast cancer and 40,430 will die of the disease in the United States in 2014.

Patients with metastatic breast cancer consist of a heterogeneous group whose clinical outcome varies depending on tumor factors, such as hormone-receptor and HER2 status and other factors, such as comorbidity and age, and anatomical site of disease. All patients with metastatic breast cancer receive systemic therapy. In certain circumstances, treatment may also involve surgery or radiation. Systemic therapy includes the use of endocrine therapy, chemotherapy, and/or HER-2 targeted therapy. Better understanding of the metastatic pathway in breast cancer has led to development and approval of several new systemic therapy agents in this setting such as everolimus, pertuzumab, and ado-trastuzumab emantansine.

Based on the drug new approvals and emerging clinical trial data, the National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer  have included new recommendations for patients with HER-2 positive metastatic breast cancer.

Selecting the optimal systemic therapy depends on the tumor burden, patient symptoms, and several other clinical factors. It is important to help clinicians understand the available and emerging clinical data and apply these in selecting the most efficient treatment strategy for patients with metastatic breast cancer of specific tumor types.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with advanced breast cancer
  • Describe the multidisciplinary aspects of the management of patients with advanced breast cancer
  • Identify the key characteristics of advanced breast cancer that trigger decision points
  • Recognize situations where optimal care may require adapting guidelines recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
06/12/2014
Course expires: 
08/07/2014
Event starts: 
06/12/2014 - 3:30pm
Event ends: 
06/12/2014 - 4:30pm
Cost:
$0.00

Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center

Ingrid Meszoely, MD
Vanderbilt-Ingram Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
06/12/2014
Course expires: 
08/07/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing